Vertaling van "breezhaler has since been launched in " (Nederlands → Frans) :

Onbrez Breezhaler has since been launched in Ireland and Denmark in March 2010 with additional launches expected this year in 20 markets, including the UK, Spain, Brazil and Mexico.
Depuis, Onbrez Breezhaler a été lancé en mars en Irlande et au Danemark et d’autres lancements sont prévus cette année dans vingt marchés, dont le Royaume-Uni, l’Espagne, le Brésil et le Mexique.

Onbrez Breezhaler (USD 5 million) has demonstrated strong performance following EU approval and since first launching in late 2009 in Germany for adult patients with chronic obstructive pulmonary disease (COPD).
Onbrez Breezhaler (USD 5 millions) a réalisé une excellente performance à la suite de son homologation dans l’UE et depuis son premier lancement à fin 2009 en Allemagne pour le traitement des adultes souffrant de broncho-pneumopathie chronique obstructive (BPCO).

Aclasta/Reclast (USD 254 million), the first once-yearly infusion therapy for various forms of osteoporosis, has now been used in more than 350,000 patients and has experienced consistent growth since its launch to treat postmenopausal osteoporosis in late 2007.
Aclasta/Reclast (USD 254 millions), première injection annuelle pour soigner différentes formes d’ostéoporose, a été utilisé par plus de 350 000 patients et a affiché une croissance notable depuis son lancement, à fin 2007, pour le traitement de l’ostéoporose potsménopausique.

Tekturna/Rasilez (USD 290 million, +104% lc), the first in a new class of medicines known as direct renin inhibitors to treat high blood pressure, has been growing consistently since its launch in 2007 based on positive clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours and superiority in clinical trials over ramipril, a leading ACE inhibitor.
Rasilez/Tekturna (USD 290 millions, +104% en m. l.), est le premier d’une nouvelle classe de médicaments, les inhibiteurs directs de la rénine, traitant l’hypertension.

Oncology has continued to build momentum since the launch of Afinitor (achieving sales of USD 67 million in the third quarter) for the treatment of patients with renal cell carcinoma (RCC), with promising data in the treatment of pancreatic tumors, as well as subependymal giant cell astrocytomas (SEGA) tumors in patients with tuberous sclerosis, which was filed in the EU and the US.
Oncologie a poursuivi son accélération depuis le lancement d’Afinitor, dont le chiffre d’affaires s’est élevé à USD 67 millions au troisième trimestre. Ce médicament, autorisé pour le traitement du carcinome des cellules rénales, se montre prometteur dans le traitement des tumeurs pancréatiques ainsi que dans le traitement de l’astrocytome sous épendymaire à cellules géantes associé à une sclérose tubéreuse, maladie pour laquelle une demande a été déposée dans l’Union européenne et aux Etats-Unis.

Exforge, a single-pill combination of Diovan (valsartan) and the calcium channel blocker amlodipine, has delivered sustained worldwide growth since its launch in 2007.
Exforge, un comprimé associant Diovan (valsartan) et l’amlodipine, un inhibiteur des canaux calciques, a affiché une croissance soutenue autour du globe depuis son lancement en 2007.

Exforge, a single-pill combination of Diovan (valsartan) and the calcium channel blocker amlodipine, has delivered consistent and sustained growth since its launch in 2007.
Exforge, un comprimé associant Diovan (valsartan) et l’amlodipine, un inhibiteur des canaux calciques, a enregistré une croissance constante et soutenue depuis son lancement en 2007.

For urgent notices, “Vit@ Express” has been launched.
For urgent notices, “Vit@ Express” has been launched.

In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.
In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.

Since 1 January 2007, the law has been in force requiring a preliminary approval for the payment by pharmaceutical companies or producers of medical devices of the participation costs of healthcare professionals in scientific events involving at least one night’s accommodation.
Since 1 January 2007, the law has been in force requiring a preliminary approval for the payment by pharmaceutical companies or producers of medical devices of the participation costs of healthcare professionals in scientific events involving at least one night’s accommodation.